MALVERN, PA--(Marketwire - April 28, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Injectable collagenase clostridium histolyticum has revolutionized treatment for Dupuytren’s contracture. In ...
This is the first part of a three-part interview from Broncos Wire's Brandon Walker with Pro Football Hall of Fame quarterback John Elway. This first story focuses on Elway's diagnosis of Dupuytren's ...
MALVERN, Pa., Nov. 20, 2024 /CNW/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment ...
June 3, 2011 (London, United Kingdom) — Injectable collagenase significantly improved range of motion and degree of contracture in patients with Dupuytren's contracture, compared with placebo, in a ...
DUBLIN--(BUSINESS WIRE)--The "Dupuytren's Disease Market Size, Share & Trends Analysis Report By Type (Diagnosis, Treatment), By Disease Type (Type I, Type II), By End-use (Hospitals, Clinics), By ...
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that ...
Injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules is effective in reducing nodule hardness and nodule size. Researchers at the Kennedy Institute, University of Oxford, led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback